{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-112002","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.510905+00:00","generated_at":"2026-06-22T23:26:20.066385+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics secures up to $1B financing from Blackstone with $350M at close","bullets":["Initial $350M at close: $300M senior secured term loan (7.25%+SOFR, 7-yr) and $50M common stock at $45.65/share.","Additional $150M delayed draw debt available for 18 months; potential $500M further financing for BD.","Collateral includes Translarna, Emflaza, Upstaza, sepiapterin, and vatiquinone assets.","Standstill restrictions on Blackstone; 90-day lock-up on stock; registration rights for resale."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-112002","json":"https://secwatch.observer/filing/0001104659-22-112002.json","markdown":"https://secwatch.observer/filing/0001104659-22-112002.md","text":"https://secwatch.observer/filing/0001104659-22-112002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/tm2229086d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:26:20.066385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"110fd47deda8fbd7aef9974247ec9c17a78b79ff","claim":"PTC THERAPEUTICS, INC. incurred credit facility of up to $950.0 million with Blackstone at adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rat maturing seven years from the Closing Date.","evidence_excerpt":"Debt Facility On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm","confidence":0.4,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $950.0 million"},{"label":"Counterparty","value":"Blackstone"},{"label":"Rate","value":"adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rat"},{"label":"Maturity","value":"seven years from the Closing Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"44dadc42355932157ae799ee4c9c86a6d7e5a090","claim":"PTC THERAPEUTICS, INC. entered into Stock Purchase Agreement with certain entities affiliated with the Lenders (the “Purchasers”) valued at approximately $50.0 million (effective 2022-10-27).","evidence_excerpt":"the Company and certain entities affiliated with the Lenders (the “Purchasers”) also entered into a stock purchase agreement on the Closing Date (the “Stock Purchase Agreement”) for the sale and issuance of 1,095,290 shares of common stock (the “Shares”) to the Purchasers at a price of $45.65 per share, for an aggregate purchase price of approximately $50.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain entities affiliated with the Lenders (the “Purchasers”)"},{"label":"Value","value":"approximately $50.0 million"},{"label":"Effective","value":"2022-10-27"}],"fact_type":"material_agreement"},{"claim_id":"6586b7b16acd5a5091e286ebf8cb33af23e280de","claim":"PTC THERAPEUTICS, INC. entered into Credit Agreement with funds and other affiliated entities advised or managed by Blackstone Life Sciences Advisors L.L.C. and Blackstone Alternative Credit Advisors LP valued at up to $950.0 million (effective 2022-10-27).","evidence_excerpt":"On October 27, 2022 (the “Closing Date”), PTC Therapeutics, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000110465922112002/0001104659-22-112002-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"funds and other affiliated entities advised or managed by Blackstone Life Sciences Advisors L.L.C. and Blackstone Alternative Credit Advisors LP"},{"label":"Value","value":"up to $950.0 million"},{"label":"Effective","value":"2022-10-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}